Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy
Hans Emanuel Oeri
Journal of Psychopharmacology (2020) Vol. 35, Iss. 5, pp. 512-536
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Lisa Burback, Suzette Brémault‐Phillips, Mirjam J. Nijdam, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 4, pp. 557-635
Closed Access | Times Cited: 96
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 52
Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Wenwen Duan, Dongmei Cao, Sheng Wang, et al.
Chemical Reviews (2023) Vol. 124, Iss. 1, pp. 124-163
Closed Access | Times Cited: 30
Therapeutic mechanisms of psychedelics and entactogens
Boris D. Heifets, David E. Olson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 104-118
Closed Access | Times Cited: 29
Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects
Patrick Vizeli, Isabelle Straumann, Urs Duthaler, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 28
Psychedelic Drugs as Treatment Agents
Rachel Yehuda, Lauren Lepow, Philip A. Bonnano, et al.
Oxford University Press eBooks (2025), pp. 999-1024
Closed Access
Examining the Role of Oxytocinergic Signaling and Neuroinflammatory Markers in the Therapeutic Effects of MDMA in a Rat Model for PTSD
Haron Avgana, Roni Shira Toledano, Irit Akirav
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 846-846
Open Access | Times Cited: 3
Psychedelics and schizophrenia: a double-edged sword
Jacopo Sapienza, Francesca Martini, Stefano Comai, et al.
Molecular Psychiatry (2024)
Closed Access | Times Cited: 3
Hallucinogenic drugs and their potential for treating fear‐related disorders: Through the lens of fear extinction
Emilija Glavonic, Miloš Mitić, Miroslav Adžić
Journal of Neuroscience Research (2022) Vol. 100, Iss. 4, pp. 947-969
Closed Access | Times Cited: 16
A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy
Robert J. Sottile, Thomas Vida
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 15
Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder
Lauren Okano, Gregory V. Jones, Bri Deyo, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 14
Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder
Collin M. Price, Allison A. Feduccia, Katrina DeBonis
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 5, pp. 464-469
Closed Access | Times Cited: 11
AddictedChem: A Data-Driven Integrated Platform for New Psychoactive Substance Identification
Mengying Han, Sheng Liu, Dachuan Zhang, et al.
Molecules (2022) Vol. 27, Iss. 12, pp. 3931-3931
Open Access | Times Cited: 8
Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
Harpreet Kaur, Sedat Karabulut, James W. Gauld, et al.
Psychedelic Medicine (2023) Vol. 1, Iss. 3, pp. 166-185
Closed Access | Times Cited: 4
Perioperative Considerations for Patients Exposed to Psychostimulants
Trent Emerick, Thomas J. Martin, Douglas G. Ririe
Anesthesia & Analgesia (2023) Vol. 137, Iss. 3, pp. 474-487
Open Access | Times Cited: 4
Modulation of functional networks related to the serotonin neurotransmitter system by citalopram: Evidence from a multimodal neuroimaging study
Daphne E. Boucherie, Liesbeth Reneman, Jan Booij, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 12, pp. 1209-1217
Open Access | Times Cited: 4
Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine
Candace B Johnson, Donna Walther, Matthew J. Baggott, et al.
Journal of Pharmacology and Experimental Therapeutics (2024), pp. JPET-001837
Open Access | Times Cited: 1
Uncovering Structure–Activity Relationships of Phenethylamines: Paving the Way for Innovative Mental Health Treatments
Sedat Karabulut, Harpreet Kaur, James W. Gauld
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 5, pp. 972-982
Closed Access | Times Cited: 1
Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A
Frederick A. Bagdasarian, Hanne D. Hansen, Jingyuan Chen, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 14, pp. 2654-2661
Closed Access | Times Cited: 1
Introduction to the chemistry and pharmacology of psychedelic drugs
Scott R. Walker, Glenn A. Pullella, Matthew Piggott, et al.
Australian Journal of Chemistry (2023) Vol. 76, Iss. 5, pp. 236-257
Open Access | Times Cited: 3
3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs
Raúl López‐Arnau, Jordi Camarasa, Marcel·lí Carbó, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 5
Modulation of functional networks related to the serotonin neurotransmitter system by citalopram: evidence from a multimodal neuroimaging study
Daphne E. Boucherie, Liesbeth Reneman, Jan Booij, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 3
<i>Corrigendum to</i>: Introduction to the chemistry and pharmacology of psychedelic drugs
Scott R. Walker, Glenn A. Pullella, Matthew Piggott, et al.
Australian Journal of Chemistry (2024) Vol. 77, Iss. 1, pp. NULL-NULL
Open Access
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns
Brian A. Baldo
Archives of Toxicology (2024) Vol. 98, Iss. 8, pp. 2409-2427
Closed Access
Page 1 - Next Page

Scroll to top